ArticleBioengineered2022

Rapamycin ameliorates chronic intermittent hypoxia and sleep deprivation-induced renal damage via the mammalian target of rapamycin (mTOR)/NOD-like receptor protein 3 (NLRP3) signaling pathway.

Wei Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.